CollPlant Biotechnologies to Participate in September Investor Conferences

REHOVOT, Israel, Sept. 6, 2022 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced that Deputy CEO and CFO Eran Rotem will participate in investor conferences later this month.

 CollPlant's 3D bioprinted regenerative breast implants -currently in the phase of a porcine study. Photo by Valerie Arad
  • HC Wainwright 24th Annual Global Investment Conference: Participate in investor meetings on Monday and Tuesday, September 12-13.

  • Alliance Global Partners MedTech Conference: Virtual investor meetings on Wednesday, September 21.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.

At the beginning of 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.

For more information about CollPlant, visit

Photo -

Contact at CollPlant:

Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600

Cision View original content:

SOURCE CollPlant